3种奥硝唑用药方案治疗慢性盆腔炎的疗效与安全性比较 点击下载
| 论文标题： | 3种奥硝唑用药方案治疗慢性盆腔炎的疗效与安全性比较 |
| 英文标题： | |
| 中文摘要： | 目的：比较3种奥硝唑用药方案治疗慢性盆腔炎（PID）的疗效和安全性。方法：120例慢性PID患者随机分为奥硝唑组（40例）、联用左氧氟沙星组（40例）和联用头孢地尼组（40例）。在常规治疗的基础上，奥硝唑组患者口服奥硝唑片0.5 g，每日早晚1次；联用左氧氟沙星组患者在奥硝唑组治疗的基础上口服盐酸左氧氟沙星片0.1 g，每日3次；联用头孢地尼组患者在奥硝唑组治疗的基础上口服头孢地尼分散片0.1 g，每日3次。3组疗程均为10 d。观察3组患者的临床疗效，治疗前后血浆黏度、红细胞压积、C反应蛋白（CRP）、白细胞介素1（IL-1）、白细胞计数、淋巴细胞计数、淋巴细胞百分比及不良反应发生情况。结果：总有效率头孢地尼组（95.00％）＞左氧氟沙星组（82.50％）＞奥硝唑组（62.50％），差异均有统计学意义（P＜0.05）。治疗前，3组患者血浆黏度、红细胞压积、CRP、IL-1、白细胞计数、淋巴细胞计数、淋巴细胞百分比比较，差异均无统计学意义（P＞0.05）；治疗后，3组患者上述指标均显著低于同组治疗前，且联用头孢地尼组＜联用左氧氟沙星组＜奥硝唑组，差异均有统计学意义（P＜0.05）。联用左氧氟沙星组患者不良反应发生率显著高于奥硝唑组和联用头孢地尼组，差异均有统计学意义（P＜0.05）；但奥硝唑组和联用头孢地尼组比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，奥硝唑联合头孢地尼治疗慢性PID的疗效显著优于奥硝唑联合左氧氟沙星和单用奥硝唑，且安全性与单用奥硝唑相近。 |
| 英文摘要： | OBJECTIVE： To compare therapeutic efficacy and safety of 3 ornidazole regimens in the treatment of chronic pelvic inflammatory disease （PID）. METHODS： A total of 120 chronic PID patients were randomly divided into ornidazole group （40 cases）， combined with levofloxacin group （40 cases） and combined with cefdinir group （40 cases）. Based on routine treatment， ornidazole group was given Ornidazole tablet 0.5 g orally， day and night. Combined with levofloxacin group was additionally given Levofloxacin hydrochloride tablet 0.1 g orally， tid， on the basis of ornidazole group. Combined with cefdinir group was additionally given Cefdinir dispersible tablet 0.1 g orally， tid， on the basis of ornidazole group. Treatment course of 3 groups lasted for 10 d. Clinical efficacies of 2 groups were observed， and plasma viscosity （PV）， hematocrit， CRP， IL-1， leucocyte count， lymphocyte count， lymphocyte percentage and the occurrence of ADR were observed before and after treatment. RESULTS： Total response rate was in descending order： combined with cefdinir group （95.00％）＞combined with levofloxacin group （82.50％）＞ornidazole group （62.50％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in PV， hematocrit， CRP， IL-1， leucocyte count， lymphocyte count or lymphocyte percentage among 3 groups （P＞0.05）. After treatment， above inelexes of 3 groups were significantly lower than before； combined with cefdinir group＜combined with levofloxacin group＜ornidazole group， there was statistical significance （P＜0.05）. The incidence of ADR in combined with levofloxacin group was significantly higher than ornidazole group and combined with cefdinir group， with statistical significance （P＜0.05）. There was no statistical significance between ornidazole group and combined with cefdinir group （P＞0.05）. CONCLUSIONS： Therapeutic efficacy of ornidazole combined with cefdinir is better than that of ornidazole combined with levofloxacin in the treatment of chronic PID， and its safety is similar to that of ornidazole alone. |
| 期刊： | 2017年第28卷第33期 |
| 作者： | 王昕雯，张慕玲 |
| 英文作者： | WANG Xinwen，ZHANG Muling |
| 关键字： | 盆腔炎；奥硝唑；头孢地尼；左氧氟沙星；疗效；安全性 |
| KEYWORDS： | Pelvic inflammatory disease； Ornidazole； Cefdinir； Levofloxacin； Therapeutic efficacy； Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！